Alzamend Neuro
ALZN
13 hedge funds and large institutions have $335K invested in Alzamend Neuro in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 12 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
1.25% less ownership
Funds ownership: 6.5% → 5.26% (-1.2%)
41% less funds holding
Funds holding: 22 → 13 (-9)
75% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 12
78% less capital invested
Capital invested by funds: $1.49M → $335K (-$1.16M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
+$30.6K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$18.2K |
| 3 |
Renaissance Technologies
New York
|
+$15.9K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$2.46K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$164 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$104K |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$24.6K |
| 3 |
Charles Schwab
San Francisco,
California
|
-$12.6K |
| 4 |
Bank of New York Mellon
New York
|
-$9.57K |
| 5 |
IIC
Integrated Investment Consultants
Bloomfield Hills,
Michigan
|
-$9.48K |
ALZN Hedge Fund Activity: Q4 2023 in Review
13 of the 6,871 institutional investors tracked by Wall St. Rank reported a position in Alzamend Neuro (ALZN) for Q4 2023, worth a combined $335K — down 78% from $1.49M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of ALZN and 3 opened new positions — a net loss of 9 holders — while 1 trimmed existing stakes and 4 added.
The largest buyer was HRT Financial, opening a new position worth an estimated $30.6K. The largest seller was Vanguard Group, cutting an estimated $104K.
- 13 institutional investors held Alzamend Neuro (ALZN) as of Q4 2023, down from 22 in Q3 2023.
- Funds reported $335K of Alzamend Neuro stock for Q4 2023, down 78% quarter-over-quarter.
- 3 funds opened new Alzamend Neuro positions in Q4 2023 and 12 closed out, a net change of -9 holders.
- The largest Alzamend Neuro buyer in Q4 2023 was HRT Financial, an estimated $30.6K added.
- The largest Alzamend Neuro seller in Q4 2023 was Vanguard Group, an estimated $104K sold.
Based on aggregated 13F filings for Q4 2023.